partner with us

Work with cutting-edge technologies

partners & Investors

NovelMed has a portfolio of innovative monoclonal antibodies with the potential to treat several different orphan and non-orphan diseases. As such, NovelMed’s antibodies are active against multiple inflammatory disorders where complement plays a pathogenetic role. NovelMed has demonstrated significant preclinical results in a variety of disease indications including; Paroxysmal Nocturnal Hemoglobinuria (PNH), Age Related Macular Degeneration (AMD), Osteoarthritis (OA) and Arthritis (RA).

Upcoming milestones & long term priorities

While our lead compound is currently in large scale production, or major objectives are to:

Locate the right pharmaceutical / biotech and/or investment partners to help us carry our years of successful development to commercialization.

Receive orphan and breakthrough status in several of our priority clinical indications.

Help initiate clinical trial programs in our leading inflammatory-mediated disease states.